Radioligand Therapy and Targeted Antigen Therapy in Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review
Objective: To review current literature about the treatment of metastatic castration-resistant prostate cancer (mCRPC) by comparing radioligand therapy (RLT) and targeted antigen therapy (TAT) to standard treatment options. Methods: Literature was gathered through PubMed and CINHAL to investigate the effectiveness of RLT with Lutetium-177 and TAT with Actinium-225 in treating this cancer. Results: The literature showed significant decrease in cancer volumes and an increase in overall survival with both treatments in patients with mCRPC. The findings indicate that TAT with Actinium-225 displayed a greater decrease in cancer volume and longer overall survival, compared to RLT with Lutetium-177. Conclusion: RLT and TAT have shown positive effects in treating patients with mCRPC compared to standard treatments like chemotherapy. More research is needed to be done to determine which treatment is more effective, Lutetium-177 or Actinium-225. Keywords: Radioligand therapy; targeted antigen therapy; metastatic castration-resistant prostate cancer; Lutetium-177; Actinium-225.